Poulton Stuart

EVP, Chief Development Officer

1 company

Excellent

Trades Analyzed

12M Win Rate

87.5%

Avg 3M Return

+17.4%

Avg 12M Return

+38.3%

Poulton Stuart is an EVP, Chief Development Officer at Karyopharm Therapeutics Inc.. Recent SEC Form 4 filings include 0 buys and 13 sells.

Estimated insider holdings value: $596K based on current market prices.

Holdings by Company

KPTIOct 15, 2025

Current Shares67.4K

Value$596.4K

Net Activity-49,964

Bought: 0Sold: 50.0K

Showing 9 filings

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Sep 15, 2025	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	401	$6.43	$2,578.43	-1.4%	+7.2%	-
Jul 29, 2025	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	191	$4.37	$834.67	-0.7%	+55.4%	-
Mar 4, 2025	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	3,548	$6.29	$22,316.92	-11.5%	-35.3%	+43.1%
Feb 18, 2025	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	5,914	$0.63	$3,725.82	-1.8%	-45.8%	-2.1%
Jul 30, 2024	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	2,883	$1.06	$3,055.98	-0.9%	-15.1%	-74.5%
Mar 1, 2024	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	22,466	$1.18	$26,469.87	-3.3%	-20.0%	-55.3%
Feb 15, 2024	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	5,847	$1.33	$7,783.44	-1.8%	-13.1%	-52.6%
Jul 28, 2023	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	2,845	$1.70	$4,836.50	-1.8%	-55.5%	-46.1%
Feb 15, 2023	KPTI Karyopharm Therapeutics Inc.	EVP, Chief Development Officer	Sell	5,869	$3.19	$18,716.55	-3.0%	-35.0%	-64.5%